CN115942933A - 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 - Google Patents

用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 Download PDF

Info

Publication number
CN115942933A
CN115942933A CN202180051106.2A CN202180051106A CN115942933A CN 115942933 A CN115942933 A CN 115942933A CN 202180051106 A CN202180051106 A CN 202180051106A CN 115942933 A CN115942933 A CN 115942933A
Authority
CN
China
Prior art keywords
compound
asthma
treatment
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051106.2A
Other languages
English (en)
Chinese (zh)
Inventor
J•卡斯特罗-帕洛米诺拉里亚
J•卡马乔戈麦斯
N·卡斯特罗-帕洛米诺拉里亚
A·阿里萨阿尔瓦雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of CN115942933A publication Critical patent/CN115942933A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202180051106.2A 2020-08-21 2021-08-20 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 Pending CN115942933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
EP20382764.7 2020-08-21
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
CN115942933A true CN115942933A (zh) 2023-04-07

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051106.2A Pending CN115942933A (zh) 2020-08-21 2021-08-20 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835766A (zh) * 2007-10-02 2010-09-15 帕罗生物制药有限公司 作为腺苷a1受体拮抗体的新化合物
CN107073114A (zh) * 2014-09-08 2017-08-18 赛福伦公司 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
CN110198939A (zh) * 2017-01-20 2019-09-03 帕罗生物制药有限公司 腺苷a3受体的调节剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835766A (zh) * 2007-10-02 2010-09-15 帕罗生物制药有限公司 作为腺苷a1受体拮抗体的新化合物
CN107073114A (zh) * 2014-09-08 2017-08-18 赛福伦公司 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
CN110198939A (zh) * 2017-01-20 2019-09-03 帕罗生物制药有限公司 腺苷a3受体的调节剂

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
PL4199922T3 (pl) 2025-02-10
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
MX2023002156A (es) 2023-03-01
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
ES3001104T3 (es) 2025-03-04
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
RU2766577C2 (ru) Способы лечения эозинофильного эзофагита
ES2645368T3 (es) Terapias para mejorar la función pulmonar
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
JP7794807B2 (ja) 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
TW202539683A (zh) 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘
CN116033900A (zh) 治疗冠状病毒暴露所致疾病的方法
US20230242652A1 (en) Treatments for atopic dermatitis
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40114122A (en) Methods of treating asthma with anti-light antibodies
HK40090654A (en) Use of dexpramipexole for the treatment of moderate to severe asthma
HK40104675A (en) Treatments for atopic dermatitis
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination